Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

629.68 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

62 63 Next >

Why Regeneron (REGN) Stock Is Falling Today

April 29, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short...

Via StockStory

Exploring the top movers within the S&P500 index during today's session. ↗

April 29, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Which S&P500 stocks are gapping on Tuesday? ↗

April 29, 2025

Looking for the S&P500 stocks that are experiencing notable gaps on Tuesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.

Via Chartmill

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday? ↗

April 29, 2025

Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and...

Via Benzinga

Topics Bonds

Tuesday's pre-market session: top gainers and losers in the S&P500 index ↗

April 29, 2025

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Via Chartmill

Regeneron Crashes 10% After Eylea Miss Drags Its Earnings Report ↗

April 29, 2025

Shares took a beating after Eylea sales came in light. Libtayo and Praluent also missed revenue forecasts.

Via Investor's Business Daily

Topics Earnings Government

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 29, 2025

Via Benzinga

Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets

April 29, 2025

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3%...

Via StockStory

Regeneron Reports First Quarter 2025 Financial and Operating Results

April 29, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

Insights into Regeneron Pharmaceuticals's Upcoming Earnings ↗

April 28, 2025

Via Benzinga

Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment. ↗

April 28, 2025

A fundamental analysis of (NASDAQ:REGN): Should Quality Investors Include NASDAQ:REGN in Their Portfolio?

Via Chartmill

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

April 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

April 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron (REGN) Reports Earnings Tomorrow: What To Expect

April 28, 2025

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.

Via StockStory

Topics World Trade

Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold ↗

April 26, 2025

Via The Motley Fool

Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal ↗

April 22, 2025

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and long-term production.

Via Benzinga

Regeneron Inks Deal With Fujifilm Diosynth Biotechnologies To Increase Manufacturing In US: Retail’s Optimistic ↗

April 22, 2025

The agreement is to manufacture and supply bulk drug products of Regeneron’s commercial biologic medicines at Fujifilm’s Holly Springs, North Carolina, campus for a period of 10 years.

Via Stocktwits

Topics Economy Stocks

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

April 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Investor Conference Presentations

April 21, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Discover which S&P500 stocks are making waves on Monday. ↗

April 21, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

Via Chartmill

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

April 18, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

April 18, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion ↗

April 17, 2025

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Via Benzinga

Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts ↗

April 17, 2025

Via Benzinga

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

April 17, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study ↗

April 15, 2025

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Via Benzinga

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

April 15, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.